InMed Pharmaceuticals (NASDAQ:INM), Inc. (NASDAQ:INM) is a clinical-stage specialty pharmaceutical company dedicated to the research, development and commercialization of cannabinoid-based therapies for a range of rare and serious conditions. Leveraging a proprietary biosynthesis and purification platform, the company focuses on creating highly pure, pharmaceutical-grade cannabinoids without the need for plant cultivation. Its pipeline includes two lead candidates: INM-755, a topical formulation designed to treat epidermolysis bullosa, a rare genetic skin disorder, and INM-088, an investigational molecule targeting neuropathic and chronic pain.
Founded in 2007 and headquartered in Vancouver, British Columbia, InMed operates both research and development facilities in Canada and the United States. The company has established strategic partnerships and collaborations to advance its pipeline, drawing on the expertise of global contract research organizations and academic institutions. Its biosynthetic technology also underpins licensing agreements aimed at broadening access to cannabinoid-based treatments in markets around the world.
InMed’s leadership team combines extensive experience in pharmaceutical development, regulatory affairs and chemical engineering. The company is led by President and Chief Executive Officer Eric A. Adams, whose background includes executive roles in life sciences firms, alongside a management group skilled in clinical operations, manufacturing and commercialization. This leadership is supported by a board of directors with diverse scientific and financial expertise.
With its focus on high-purity, reproducible cannabinoid compounds, InMed Pharmaceuticals seeks to address unmet medical needs in niche patient populations. By advancing its product candidates through clinical trials and establishing scalable manufacturing processes, the company aims to become a leading provider of novel cannabinoid therapies in global specialty markets.
